Email updates

Keep up to date with the latest news and content from JTM and BioMed Central.

Open Access Highly Accessed Review

Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy

Tristan D Yan, Oswald A Stuart, Dal Yoo and Paul H Sugarbaker*

Author Affiliations

Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington DC, USA

For all author emails, please log on.

Journal of Translational Medicine 2006, 4:17  doi:10.1186/1479-5876-4-17

Published: 10 April 2006

Abstract

The treatment of peritoneal surface malignancy mainly focuses on diffuse malignant peritoneal mesothelioma, pseudomyxoma peritonei from appendiceal cancer, and peritoneal dissemination from gastrointestinal and ovarian cancers. Cancer progression causes peritoneal implants to be distributed throughout the abdominopelvic cavity. These nodules plus the ascitic fluid result in abdominal distension. As the disease progresses, these tumors cause intestinal obstruction leading to debilitating symptoms and a greatly impaired quality of life. In the past, the prognosis of patients with peritoneal surface malignancy was regarded dismal and cure was not an option. Recently, cytoreductive surgery combined with perioperative intraperitoneal chemotherapy has shown an improved survival in selected patients with this disease. To date, multiple different treatment regimens of perioperative intraperitoneal chemotherapy have been used. This review focuses on the perioperative intraperitoneal chemotherapy currently in use in conjunction with cytoreductive surgery for the treatment of peritoneal surface malignancy at the Washington Cancer Institute.